Symbicort: a pharmacoeconomic review

References

• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59: 469–478.
   PubMed Web of Science ®Google Scholar
• Haahtela T, Laitinen LA. Asthma programme in Finland 1994-2004. Report of a Working Group. Clinical & Experimental Allergy 1996; 26((Suppl. 1))1–24.
   Google Scholar
• Federico MJ, Liu AH. Overcoming childhood asthma disparities of the innercity poor. Pediatric Clinics of North America 2003; 50: 655–675.
   PubMed Web of Science ®Google Scholar
• Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology 2001; 107((1))3–8.
   Google Scholar
• National Heart Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, MD: National Institutes of Health 2007.
   Google Scholar
• Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. Journal of Allergy and Clinical Immunology 2002; 109: 264–270.
   PubMed Web of Science ®Google Scholar
• Schwenkglenks M, Lowy A, Anderhub H, Szucs TD. Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value in Health 2003; 6: 75–83.
   Google Scholar
• Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. European Respiratory Journal 2002; 20: 260–267.
   PubMed Web of Science ®Google Scholar
• Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-year prospective study. European Respiratory Journal 2002; 19: 61–67.
   PubMed Web of Science ®Google Scholar
• Bootman JL, Crown WH, Luskin AT. Clinical and economic effects of suboptimally controlled asthma. Managed Care Interface 2004; 17: 31–36.
   PubMedGoogle Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2006 [cited 2007 Dec]; Available from: http://www.ginasthma.com
   Google Scholar
• British guideline on the management of asthma. Thorax 2003; 58((Suppl. 1))i1–i94.
   Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine 1997; 337: 1405–1411.
   PubMed Web of Science ®Google Scholar
• Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123((5))1480–1487.
   Google Scholar
• Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. American Journal of Respiratory Critical Care Medicine 2000; 161: 996–1001.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61((2))164–168.
   Google Scholar
• Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118((5))1278–1285.
   Google Scholar
• European Respiratory Society and European Lung Foundation. European Lung White Book. Lausanne: European Respiratory Society 2003.
   Google Scholar
• Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19((6))623–642.
   Google Scholar
• Calverley P, Sondhi S. The burden of obstructive lung disease in the UK - COPD and asthma. Thorax 1998; 53((Suppl. 4))A83.
   Google Scholar
• Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respiratory Medicine 2003; 97((Suppl. C))S3–S14.
   Google Scholar
• Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respiratory Medicine 2003; 97((Suppl. C))S71–S79.
   PubMedGoogle Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123((3))784–791.
   Google Scholar
• Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respiratory Medicine 2002; 96((9))700–708.
   Google Scholar
• Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) [published erratum appears in American Journal of Respiratory Critical Care Medicine 1997; 155(1): 386]. American Journal of Respiratory Critical Care Medicine 1996; 154(4 Pt 1): 959–967.
   Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory Critical Care Medicine 2007; 176((6))532–555.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease. National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59((Suppl. 1))1–232.
   Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal 2003; 22((6))912–919.
   Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal 2003; 21((1))74–81.
   Google Scholar
• Rosenhall L, Borg S, Andersson F, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. International. Journal of Clinical Practice 2003; 57((8))662–667.
   Google Scholar
• Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respiratory Medicine 2006; 100((4))586–594.
   Google Scholar
• Doull I, Price D, Thomas M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Current Medical Research and Opinion 2007; 23((5))1147–1159.
   Google Scholar
• Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respiratory Medicine 2006; 100((7))1152–1162.
   Google Scholar
• Bruggenjurgen B, Selim D, Kardos P, et al. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005; 23((7))723–731.
   Google Scholar
• Price D, Haughney J, Lloyd A, Hutchinson J, Plumb J. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Current Medical Research and Opinion 2004; 20((10))1671–1679.
   Google Scholar
• Canonica GW, Castellani P, Cazzola M, et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulmonary Pharmacology & Therapeutics 2004; 17((4))239–247.
   Google Scholar
• Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion 2004; 20((2))225–240.
   Google Scholar
• FitzGerald JM, Sears MR, Boulet LP, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Canadian Respiratory Journal 2003; 10((8))427–434.
   Google Scholar
• Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006; 24((7))695–708.
   Google Scholar
• Lundborg M, Wille S, Bjermer L, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Current Medical Research and Opinion 2006; 22((5))809–821.
   Google Scholar
• Bousquet J, Boulet L, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respiratory Medicine 2007; 101: 2437–2446.
   PubMed Web of Science ®Google Scholar
• Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007; 62((10))1189–1198.
   Google Scholar
• Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal 2007; 14((5))269–275.
   Google Scholar
• Lofdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23((4))365–375.
   Google Scholar
• Dal Negro R, Eandi M, Pradelli L, Iannazzo S. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2007; 2((2))169–176.
   Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361((9356))449–456.
   PubMedGoogle Scholar
• Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respiratory Medicine 2008; 102((1))92–101.
   Google Scholar
• British National Formulary 54. 2007.
   Google Scholar
• Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice 2007; 61((5))725–736.
   Google Scholar
• Drummond MF, Pang F. Trasferability of economic evaluation results. In:. Economic Evaluation in Health Care: Merging Theory with Practice., MF Drummond, A, eds. McGuire. Oxford: Oxford University Press. 2001; 256–276.
   Google Scholar